High Vista Strategies LLC Krystal Biotech, Inc. Transaction History

High Vista Strategies LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$108.01 - $179.35 $423,723 - $703,590	3,923 New	3,923 $698,000
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $202,045 - $242,469	1,862 Added 73.6%	4,392 $509,000
Q2 2023 Aug 14, 2023	SELL	$78.48 - $130.32 $669,277 - $1.11 Million	-8,528 Reduced 77.12%	2,530 $297,000
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $254,012 - $321,437	4,023 Added 57.19%	11,058 $876,000
Q3 2022 Nov 14, 2022	SELL	$64.85 - $82.4 $336,571 - $427,656	-5,190 Reduced 42.45%	7,035 $490,000
Q2 2022 Aug 15, 2022	BUY	$48.93 - $73.47 $598,169 - $898,170	12,225 New	12,225 $803,000

311

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $5.05B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.